Education
About Us
Working with TipRanks
Follow Us
Incyte Corp (INCY)
NASDAQ:INCY
INCY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$53.56 - $83.95
Previous CloseN/A
Volume384.35K
Average Volume (3M)1.90M
Market Cap
$13.21B
Enterprise Value$11.31B
Total Cash (Recent Filing)$2.41B
Total Debt (Recent Filing)$43.12M
Price to Earnings (P/E)214.2
Beta0.55
Next Earnings
Jul 29, 2025EPS Estimate
1.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.16
Shares Outstanding193,569,930
10 Day Avg. Volume1,419,607
30 Day Avg. Volume1,896,236
Financial Highlights & Ratios
PEG Ratio24.91
Price to Book (P/B)3.61
Price to Sales (P/S)0.00
P/FCF Ratio45.83
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue0.68
Enterprise Value/Gross Profit2.78
Enterprise Value/Ebitda9.68
Forecast
1Y Price Target
$79.60Price Target Upside15.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
Incyte News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessINCA33989 showed high overall response rates and molecular responses with relative normalization of platelets.
Leadership ChangeThe decision to replace Mr. Hoppenot with Mr. Meury is likely to be positive for INCY shares, given Mr. Meury's historical record of leading companies that were ultimately acquired.
Product DevelopmentThe FDA approved Monjuvi in combination with rituximab and lenalidomide in 2L+ follicular lymphoma, adding to Monjuvi's existing approval in 2L+ DLBCL.
Bears Say
Loss Of ExclusivityJakafi's loss of exclusivity in the late 2020s is a significant concern for the company.
R&D And Market CompetitionThe market for R/R FL treatments is becoming increasingly competitive with other approved treatments showing strong efficacy.
Revenue ChallengesOur Underperform rating on INCY shares is supported by our fundamental analysis suggesting Opzelura revenue will be challenged by lower tube usage.
Ownership Overview
15.70% Insiders
22.90% Mutual Funds
0.60% Other Institutional Investors
34.48% Public Companies and Individual Investors
INCY FAQ
What was Incyte Corp’s price range in the past 12 months?
Incyte Corp lowest stock price was $53.56 and its highest was $83.95 in the past 12 months.
What is Incyte Corp’s market cap?
Incyte Corp’s market cap is $13.21B.
When is Incyte Corp’s upcoming earnings report date?
Incyte Corp’s upcoming earnings report date is Jul 29, 2025 which is in 11 days.
How were Incyte Corp’s earnings last quarter?
Incyte Corp released its earnings results on Apr 29, 2025. The company reported $1.16 earnings per share for the quarter, beating the consensus estimate of $0.978 by $0.182.
Is Incyte Corp overvalued?
According to Wall Street analysts Incyte Corp’s price is currently Undervalued.
Does Incyte Corp pay dividends?
Incyte Corp does not currently pay dividends.
What is Incyte Corp’s EPS estimate?
Incyte Corp’s EPS estimate is 1.42.
How many shares outstanding does Incyte Corp have?
Incyte Corp has 193,569,930 shares outstanding.
What happened to Incyte Corp’s price movement after its last earnings report?
Incyte Corp reported an EPS of $1.16 in its last earnings report, beating expectations of $0.978. Following the earnings report the stock price went up 1.529%.
Which hedge fund is a major shareholder of Incyte Corp?
Currently, no hedge funds are holding shares in INCY
Incyte Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$79.60 (15.46% Upside)
$79.60 (15.46% Upside)
Blogger Sentiment
Bullish
INCY Sentiment 80%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 88.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 5.8%
Last 30 Days ▼ 5.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.17%
12-Months-Change
Fundamentals
Return on Equity
0.47%
Trailing 12-Months
Asset Growth
-19.43%
Trailing 12-Months
Company Description
Incyte Corp
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
INCY Company Deck
INCY Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong financial performance with significant revenue growth, successful product launches, and positive R&D progress. While there are potential challenges related to inventory management and competitive pressures, the overall sentiment remains optimistic due to the company's robust cash position and strategic planning.Read More>INCY Revenue Breakdown
85.33% Product revenues, net
13.66% Product royalty revenues
1.01% Milestone and contract revenues
INCY Stock 12 Month Forecast
Average Price Target
$79.60
▲(15.46%Upside)